Monograph Details
|
|
Neoplasms
> Alkylating agents
|
|
EMCYT |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Estramustine phosphate sodium (prodrug of estradiol) 140mg; caps. |
| Indications |
|
Palliative of metastatic, progressive prostate cancer. |
| Children |
|
Not applicable. |
| Adults |
|
Take 1 hour before or 2 hours after meals. 14mg/kg in 3 or 4 divided doses; reevaluate after 30 to 90 days. Continue as long as favorable response maintained. |
| Contraindications |
|
Active thrombophlebitis or thromboembolic disorders (except when tumor mass caused by thromboembolic phenomenon). Allergy to estradiol, nitrogen mustard. |
| Precautions |
|
History of thrombophlebitis, thrombosis, thromboembolic disorders. Cerebro- or cardiovascular disease. Diabetes. Hypertension. Conditions aggravated by fluid retention. Renal or hepatic dysfunction. Monitor bilirubin and hepatic enzymes during and for 2 months after treatment is discontinued. Metabolic bone diseases associated with hypercalcemia. Use effective contraception. |
| Interactions |
|
Absorption impaired by calcium. |
| Adverse Reactions |
|
Edema, dyspnea, leg cramps; nausea, diarrhea, GI upset; pruritus, dry skin, easy bruising; breast tenderness and enlargement; lethargy, emotional lability, insomnia; leucopenia; abnormal bilirubin, LDH, SGOT. Thrombosis, MI. |
| How Supplied |
|
Caps—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
